Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2

Molecular Cancer Therapeutics

Volumn 13, Issue 5, 2014, Pages 1194-1205

  Liu, Suhu ^a,b   Walker, Sarah R ^a,b   Nelson, Erik A ^a,b   Cerulli, Robert ^a,b   Xiang, Michael ^a,b   Toniolo, Patricia A ^a,b,c   Qi, Jun ^a,b   Stone, Richard M ^a,b   Wadleigh, Martha ^a,b   Bradner, James E ^a,b   Frank, David A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN 2 PROTEIN; BROMODOMAIN INHIBITOR; CYTOKINE; IMATINIB; JAK INHIBITOR 1; JANUS KINASE INHIBITOR; JQ 1; NILOTINIB; PROTEIN; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BRD2 PROTEIN, HUMAN; GSK525762A; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; TRIAZOLE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE T CELL LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LYMPHOMA; LYMPHOMA CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; REPORTER GENE; T CELL LEUKEMIA; TRANSCRIPTION REGULATION; UMBILICAL CORD BLOOD; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; TUMOR CELL LINE;

AZEPINES; BENZODIAZEPINES; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; STAT5 TRANSCRIPTION FACTOR; TRIAZOLES;

EID: 84899840925     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0341     Document Type: Article

References (38)

1. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000;19:2496-504.
2. Sternberg DW, Gilliland DG. The role of signal transducer and activator of transcription factors in leukemogenesis. Am J Clin Oncol 2004;22:361-71.
3. Scheeren FA, Diehl SA, Smit LA, Beaumont T, Naspetti M, Bende RJ, et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008;111:4706-15.
4. Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, et al. Clarifying the role of Stat5 in lymphoid development and Abelsoninduced transformation. Blood 2006;107:4898-906.
5. Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and Jak2V617F in mice. Blood 2012;119: 3550-60.
6. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011;117:3409-20.
7. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, et al. BCL6 enables Ph acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011;473:384-8.
8. Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, et al. Philadelphia-positive patients who already harbor imatinibresistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009;114: 2168-71.
9. Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 2008;112:3847-55.
10. Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, et al. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 2012;8:285-93.
11. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011;117:3421-9.
12. Bar-Natan M, Nelson EA, Walker SR, Kuang Y, Distel RJ, Frank DA. Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells. Leukemia 2012;26:1407-10.
13. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478: 529-33.
14. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med 2012;367:647-57.
15. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.
16. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008;112:5095-102.
17. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010;468:1119-23.
18. Nelson EA, Walker SR, Alvarez JV, Frank DA. Isolation of unique STAT5 targets by chromatinimmunoprecipitation-based gene identification. J Biol Chem 2004;279:54724-30.
19. Nelson EA, Walker SR, Li W, Liu XS, Frank DA. Identification of human STAT5-dependent gene regulatory elements based on interspecies homology. J Biol Chem 2006;281:26216-24.
20. Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 2007;26:224-33.
21. Dumon S, Santos SC, Debierre-Grockiego F, Gouilleux-Gruart V, Cocault L, Boucheron C, et al. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene 1999;18:4191-9.
22. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000;96:2269-76.
23. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, et al. Pim-1 is upregulated by constitutively activated FLT3 and plays a role in FLT3- mediated cell survival. Blood 2005;105:1759-67.
24. LeRoy G, Rickards B, Flint SJ. The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell 2008; 30:51-60.
25. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, et al. BET bromodomain inhibition targets both c-MYC and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012;120:2843-52.
26. Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 2008;22: 1117-24.
27. Frank DA. STAT signaling in cancer: Insights into pathogenesis and treatment strategies. Cancer Treat Res 2003;115:267-91.
28. Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 2009;27:4422-32.
29. Heuser M, Sly LM, Argiropoulos B, Kuchenbauer F, Lai C,WengA, et al. Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood 2009;114:3983-93.
30. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, et al. FLT3-ITDup-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009;114:5034-43.
31. Fatrai S, Wierenga AT, Daenen SM, Vellenga E, Schuringa JJ. Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells. Blood 2011;117:3320-30.
32. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
33. Denis GV, Vaziri C, Guo N, Faller DV. RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ 2000;11:417-24.
34. Jiang YW, Veschambre P, Erdjument-Bromage H, Tempst P, Conaway JW, Conaway RC, et al. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc Natl Acad Sci U S A 1998;95:8538-43.
35. Greenwald RJ, Tumang JR, Sinha A, Currier N, Cardiff RD, Rothstein TL, et al. E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 2004;103:1475-84.
36. Denis GV, Green MR. A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator. Genes Dev 1996; 10:261-71.
37. Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, et al. The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations. Genes Cancer 2012;3:503-11.
38. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.